United States & Moderna

United States: The United States is the primary market for the mFlusiva vaccine, with tens of thousands of Americans dying from influenza annually. The approval of this mRNA vaccine could significantly impact public health strategies and pandemic preparedness within the country.

Moderna: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.